28 November 2019 - Hutchison China MediTech today announces that Elunate (fruquintinib capsules), its national class 1 targeted anticancer drug for the treatment of patients with advanced colorectal cancer, has been included in the updated National Reimbursement Drug List released by China’s National Healthcare Security Administration.

“Elunate is Chi-Med’s first novel oncology drug commercially launched in China,” commented Mr. Christian Hogg, Chief Executive Officer of Chi-Med. “The inclusion in the NRDL is a very important step forward to broaden availability and patient access to Elunate across China. We now look forward to our partner, Eli Lilly and Company, to capitalise on the opportunity provided by this important government policy to accelerate the accessibility of Elunate to patients across China.”

Read Hutchison China MediTech press release